3 years ago

Spirea Raises £2.4 Million to Develop New Generation of Antibody Drug Conjugates

  • Spirea, a UK-based company developing a new generation of antibody drug conjugate (ADC) therapeutics, has secured £2.4 million in funding

  • The round was co-led by Jonathan Milner and Cambridge Enterprise, with participation from R42 Group, ACF Investors, o2h Ventures, Syndicate Room, and the Cambridge Angels

  • The company will utilize the funds to advance its pipeline of differentiated ADCs for the treatment of solid tumors

  • Spirea's technology platform allows for a higher drug-to-antibody ratio, enabling the development of more effective and safer cancer therapeutics.

      • ProblemHealthcare

      "improving the efficacy and safety of antibody drug conjugates (ADCs) in treating solid tumours"

      Solution

      "developing ADCs with a higher drug-to-antibody ratio to deliver more cytotoxic drug to cancer cells"

      Covered on